PureTech Health PLC
NASDAQ:PRTC

Watchlist Manager
PureTech Health PLC Logo
PureTech Health PLC
NASDAQ:PRTC
Watchlist
Price: 18.67 USD -2.02% Market Closed
Market Cap: $446.8m

Net Margin

1 071%
Current
Improving
by 4 942.2%
vs 3-y average of -3 871.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1 071%
=
Net Income
$50.7m
/
Revenue
$6.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
1 071%
=
Net Income
$50.7m
/
Revenue
$6.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
PureTech Health PLC
LSE:PRTC
326.8m GBP
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.1B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Higher than 99% of companies in the United States of America
Percentile
99th
Based on 15 072 companies
99th percentile
1 071%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

PureTech Health PLC
Glance View

Market Cap
446.8m USD
Industry
Biotechnology

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.

PRTC Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
1 071%
=
Net Income
$50.7m
/
Revenue
$6.4m
What is PureTech Health PLC's current Net Margin?

The current Net Margin for PureTech Health PLC is 1 071%, which is above its 3-year median of -3 871.3%.

How has Net Margin changed over time?

Over the last 3 years, PureTech Health PLC’s Net Margin has increased from -88.5% to 1 071%. During this period, it reached a low of -22 290.9% on Jun 30, 2024 and a high of 1 387% on Dec 31, 2024.

Back to Top